Comments

Elevation Oncology

ELEVNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$2.89
-0.1-3.51%
At Close: -
$2.95
0.062.08%
After Hours: 4:00 PM EDT
15 minutes delayed
Elevation Oncology (ELEV) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$12.00
Lowest Price Target1
$1.00
Consensus Price Target1
$7.50

want to know what
the Bulls & Bears Say?

Elevation Oncology (NASDAQ:ELEV) Stock, Analyst Ratings, Price Targets, Forecasts

Elevation Oncology Inc has a consensus price target of $7.5 based on the ratings of 11 analysts. The high is $12 issued by HC Wainwright & Co. on December 23, 2021. The low is $1 issued by SVB Leerink on January 9, 2023. The 3 most-recent analyst ratings were released by JMP Securities, JMP Securities, and Piper Sandler on July 15, 2024, June 28, 2024, and May 31, 2024, respectively. With an average price target of $8 between JMP Securities, JMP Securities, and Piper Sandler, there's an implied 171.19% upside for Elevation Oncology Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
3
May
0
0
0
0
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JMP Securities
Piper Sandler
Stephens & Co.
Wedbush
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Elevation Oncology

Buy NowGet Alert
07/15/2024Buy Now137.29%JMP Securities
Silvan Tuerkcan
$7 → $7ReiteratesMarket Outperform → Market OutperformGet Alert
06/28/2024Buy Now137.29%JMP Securities
Silvan Tuerkcan
$7 → $7ReiteratesMarket Outperform → Market OutperformGet Alert
05/31/2024Buy Now238.98%Piper Sandler
Biren Amin
 → $10Initiates → OverweightGet Alert
05/14/2024Buy Now171.19%Stephens & Co.
Sudan Loganathan
 → $8Initiates → OverweightGet Alert
05/03/2024Buy Now171.19%Wedbush
Robert Driscoll
 → $8ReiteratesOutperform → OutperformGet Alert
04/09/2024Buy Now103.39%HC Wainwright & Co.
Swayampakula Ramakanth
 → $6ReiteratesBuy → BuyGet Alert
03/07/2024Buy Now137.29%JMP Securities
Silvan Tuerkcan
 → $7ReiteratesMarket Outperform → Market OutperformGet Alert
03/07/2024Buy Now171.19%Wedbush
Robert Driscoll
$5 → $8MaintainsOutperformGet Alert
03/07/2024Buy Now103.39%HC Wainwright & Co.
Swayampakula Ramakanth
 → $6ReiteratesBuy → BuyGet Alert
03/01/2024Buy Now137.29%JMP Securities
Silvan Tuerkcan
 → $7Initiates → Market OutperformGet Alert
02/20/2024Buy Now103.39%HC Wainwright & Co.
Swayampakula Ramakanth
$1.5 → $6MaintainsBuyGet Alert
11/06/2023Buy Now69.49%Wedbush
Robert Driscoll
 → $5ReiteratesOutperform → OutperformGet Alert
09/29/2023Buy Now-49.15%HC Wainwright & Co.
Swayampakula Ramakanth
 → $1.5Initiates → BuyGet Alert
06/05/2023Buy Now103.39%Wedbush
Robert Driscoll
$4 → $6MaintainsOutperformGet Alert
05/30/2023Buy Now171.19%SVB Securities
Andrew Berens
$5 → $8UpgradeMarket Perform → OutperformGet Alert
03/10/2023Buy Now35.59%Wedbush
Robert Driscoll
 → $4Reiterates → OutperformGet Alert
01/09/2023Buy Now-66.1%SVB Leerink
Andrew Berens
$2 → $1MaintainsMarket PerformGet Alert
11/10/2022Buy Now—JP Morgan
Anupam Rama
—DowngradeNeutral → UnderweightGet Alert
11/07/2022Buy Now-32.2%SVB Leerink
Andrew Berens
$11 → $2DowngradeOutperform → Market PerformGet Alert
09/19/2022Buy Now154.24%HC Wainwright & Co.
Gobind Singh
 → $7.5Assumes → BuyGet Alert
08/08/2022Buy Now—JP Morgan
Anupam Rama
—DowngradeOverweight → NeutralGet Alert
03/04/2022Buy Now611.86%Wedbush
Robert Driscoll
$27 → $21MaintainsOutperformGet Alert
12/23/2021Buy Now306.78%HC Wainwright & Co.
Michael King
 → $12Initiates → BuyGet Alert
07/20/2021Buy Now815.25%Wedbush
Robert Driscoll
—Initiates → OutperformGet Alert
07/20/2021Buy Now—Cowen & Co.
Marc Frahm
—Initiates → OutperformGet Alert
07/20/2021Buy Now577.97%SVB Leerink
Andrew Berens
—Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Elevation Oncology (ELEV) stock?

A

The latest price target for Elevation Oncology (NASDAQ:ELEV) was reported by JMP Securities on July 15, 2024. The analyst firm set a price target for $7.00 expecting ELEV to rise to within 12 months (a possible 137.29% upside). 13 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Elevation Oncology (ELEV)?

A

The latest analyst rating for Elevation Oncology (NASDAQ:ELEV) was provided by JMP Securities, and Elevation Oncology reiterated their market outperform rating.

Q

When was the last upgrade for Elevation Oncology (ELEV)?

A

The last upgrade for Elevation Oncology Inc happened on May 30, 2023 when SVB Securities raised their price target to $8. SVB Securities previously had a market perform for Elevation Oncology Inc.

Q

When was the last downgrade for Elevation Oncology (ELEV)?

A

The last downgrade for Elevation Oncology Inc happened on November 10, 2022 when JP Morgan changed their price target from N/A to N/A for Elevation Oncology Inc.

Q

When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.

Q

Is the Analyst Rating Elevation Oncology (ELEV) correct?

A

While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $7.00 to $7.00. The current price Elevation Oncology (ELEV) is trading at is $2.95, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch